Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Pediatric Infectious Disease Journal"
DOI: 10.1097/inf.0000000000002437
Abstract: BACKGROUND The burden of human papillomavirus (HPV) diseases is high in Latin America. HPV vaccines licensed from 2006 onwards offer protection against most HPV-related cancers, especially when introduced into national immunization programs. Barriers to optimal… read more here.
Keywords: as04 adjuvanted; vaccine; human papillomavirus; year ... See more keywords
Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study
Sign Up to like & getrecommendations! Published in 2020 at "Asia-Pacific Journal of Clinical Oncology"
DOI: 10.1111/ajco.13398
Abstract: In 9‐17‐year‐old Chinese girls, the AS04‐adjuvanted HPV‐16/18 vaccine (AS04‐HPV‐16/18) given as three‐dose schedule induced high antibody levels, which were noninferior 1 month after the third dose to those observed in 18‐25‐year‐old Chinese women in a… read more here.
Keywords: adjuvanted hpv; hpv vaccine; year; chinese girls ... See more keywords